Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived mesenchymal stem cells (IMSS)
- Development stage
- Unknown
- Lead developer
- Instituto Mexicano del Seguro Social
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Topical
01
Overview
Investigational autologous cell therapy developed by the Instituto Mexicano del Seguro Social (IMSS) for the treatment of mandibular fractures. The therapy utilizes mesenchymal stem cells (MSCs) derived from the patient's own adipose tissue, which are harvested 24 hours prior to the surgical procedure. During the surgery for fracture reduction, these autologous mesenchymal stem cells (AMSCs) are applied directly to the fracture site. The primary mechanism of action is to promote bone regeneration and neoformation, thereby reducing healing time and improving the quality of the resulting bone. Results from a Phase 3 clinical trial (NCT02755922) indicated a significantly higher ossification rate in patients treated with AMSCs compared to those receiving standard surgical reduction alone.
- Other names
- AMSCsautologous mesenchymal stem cellsadipose-derived mesenchymal stem cells
Beyond the preview
Go deeper on autologous adipose-derived mesenchymal stem cells (IMSS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived mesenchymal stem cells (IMSS).